Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE2: BMT vs Standard Care in Severe Sickle Cell Disease
NCT02766465Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Mar 2017
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Overall Survival at 2 years. Started Mar 2017; status: completed.
Beyond the preview
Go deeper on NCT02766465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766465.